Latest Neuroendocrine tumor Stories
-- Telotristat etiprate, a Phase 3 compound for the treatment of carcinoid syndrome PARIS and THE WOODLANDS, Texas, Oct.
- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER,
Clinical Trials Will Continue to Play a Key Role in this Growing Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept.
Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals,
Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader
SAINT-GENIS-POUILLY, France, March 4, 2014 /PRNewswire/ -- Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM),
BerriHealth continues to support research for the neuroendocrine tumor and carcinoid cancer community. Portland, Oregon (PRWEB) February 21, 2014 BerriHealth,
From Patient to Survivor: Author’s Medical Background and Own Cancer Experience Provides Insight and Inspiration for Rare Type of Cancer San Francisco (PRWEB)
DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q8l6jf/lexicons) has announced the addition of the "Lexicon's
Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.